Actively Recruiting
Open-Label Study Evaluating NGGT002 Gene Therapy for Adults With Classic Phenylketonuria
Led by NGGT INC. · Updated on 2026-08-18
12
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of NGGT002 gene therapy in adults with classic Phenylketonuria PKU, a condition marked by severe deficiency of the PAH enzyme. This Phase 12, open-label study involves multiple centers and includes dose escalation and cohort expansion to determine the best dosing for this treatment. NGGT002 uses an rAAV8 vector to deliver a functional human PAH gene to participants. Participants will receive a single intravenous infusion of NGGT002 at either a low or high dose. Initially, three subjects will receive the low dose with staggered dosing. Depending on safety and efficacy results, the low dose cohort may be expanded or escalated to the high dose with additional participants. The study has two parts, each assessing these dosing strategies, and may stop or proceed based on ongoing evaluations. Participants will be followed for safety and efficacy for up to five years after dosing. Researchers will monitor adverse events, laboratory values, vital signs, ECGs, and plasma phenylalanine levels at regular intervals. Participants will also record their diet and complete quality of life questionnaires. Safety monitoring includes long-term follow-up to evaluate the impact of NGGT002 over time.
CONDITIONS
Brief Title
AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
Research Team
S
Study Contact
J
Jinpeng Zhu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here